SAMSUNG BIOLOGICS CO.,LTD.
Financials
Valuation Metrics
SAMSUNG BIOLOGICS CO.,LTD.'s Market Cap is ₩68.3T. At end of 2025 it was ₩78.5T. Ranked #7 of 2,436 in KR market (top 0.3%), #7 of 787 on KOSPI (top 0.9%), #1 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 68.33T KRW | KR#7/2,436 Sec#1/234 |
| Revenue | 4.52T KRW | KR#135/2,436 Sec#1/234 |
| Net Income | 1.88T KRW | KR#24/2,436 Sec#1/234 |
| Total Assets | 11.99T KRW | KR#99/2,436 Sec#2/234 |
| Net Assets | 7.92T KRW | KR#66/2,436 Sec#2/234 |
| Employees | 5,011 | KR#59/2,436 Sec#1/234 |
| Value | ||
| P/E | 36.38x | KR#1,300/2,436 Sec#83/234 |
| P/B | 8.62x | KR#2,323/2,436 Sec#205/234 |
| PEG | 1.46x | KR#781/2,436 Sec#49/234 |
| P/S | 15.13x | KR#2,313/2,436 Sec#174/234 |
| EV/EBITDA | 31.77x | KR#1,207/2,436 Sec#81/234 |
| FCF Yield | 1.25% | KR#1,128/2,436 Sec#79/234 |
| Profitability | ||
| ROE | 23.70% | KR#85/2,436 Sec#7/234 |
| ROA | 15.66% | KR#69/2,436 Sec#7/234 |
| Op. Margin | 47.90% | KR#16/2,436 Sec#2/234 |
| Revenue Growth | -3.17% | KR#1,620/2,436 Sec#152/234 |
| Earnings Growth | 24.95% | KR#721/2,436 Sec#45/234 |
| Financial Health | ||
| Debt Ratio | 51.40% | KR#183/2,436 Sec#23/234 |
| Total Debt | 918.90B KRW | KR#208/2,436 Sec#5/234 |
| FCF | 856.07B KRW | KR#39/2,436 Sec#1/234 |
| Cash | 520.36B KRW | KR#148/2,436 Sec#2/234 |
| Current Ratio | 1.70x | KR#1,149/2,436 Sec#125/234 |
| Net Debt/EBITDA | 0.18x | KR#714/2,436 Sec#48/234 |
| Performance | ||
| 1Y Return | -4.30% | KR#809/2,436 Sec#60/234 |
| 1M Return | 3.87% | KR#545/2,436 Sec#47/234 |
| From 52W High | -25.72% | KR#282/2,436 Sec#17/234 |
| 1Y MDD | -36.74% | KR#397/2,436 Sec#28/234 |
| Trading | ||
| Volume | 51,711 shares | KR#1,307/2,436 Sec#128/234 |
| Foreign Own. | 12.93% | KR#380/2,436 Sec#31/234 |
| Per Share | ||
| EPS | 30,779 KRW | KR#18/2,436 Sec#1/234 |
| BPS | 171,343 KRW | KR#71/2,436 Sec#3/234 |
Company Info
Established in 2011, this company is a biopharmaceutical CDMO specialist that incorporated development and commercialization divisions by acquiring 100% of Samsung Bioepis shares in 2022. It operates production facilities in Songdo, Incheon, offering contract manufacturing and cell line/process development services, and currently sells 10 types of biosimilars globally. The company is expanding from antibody drug-focused CDMO to next-generation biopharmaceuticals, aiming to complete an End-to-End service system with the launch of an organoid business in 2025. Samsung Biologics is headquartered in Yeonsu-gu, Incheon.